# Medtronic plc (MDT) financials

Medtronic plc reported revenue of $36.4 billion for fiscal year 2026 (the twelve months to 24 Apr 2026), up 8.4% from fiscal 2025. Net income was $4.80 billion and diluted earnings per share $3.73.

In its latest reported quarter, the first quarter of fiscal 2027 (the three months to 31 Jul 2026), revenue was $9.76 billion, up 13.7% from a year earlier.

Source: Medtronic plc's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 3 Sep 2026. Amounts in USD. Page: https://aapwire.com/stocks/MDT. Retrieved 2026-11-16.

## Latest results: Q1 FY2027

Medtronic plc reported revenue of $9.76 billion, up 13.7% from a year earlier, net income of $1.47 billion and diluted earnings per share of $1.14 against $0.81 for the first quarter of fiscal 2027 (the three months to 31 Jul 2026).

From its quarterly report, the results first announced on 1 Sep 2026.

| Measure | Q1 FY2027 | Q1 FY2026 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $9.76B | $8.58B | +13.7% |
| Gross profit | $6.34B | $5.58B | +13.7% |
| Gross margin | 65.0% | 65.0% | −0.0 pts |
| Operating income | $1.76B | $1.45B | +22.1% |
| Operating margin | 18.1% | 16.8% | +1.2 pts |
| Net income | $1.47B | $1.04B | +41.3% |
| Diluted EPS | $1.14 | $0.81 | +40.7% |
| Operating cash flow | $1.79B | $1.09B | +64.8% |
| Capital expenditure | $503.0M | $504.0M | −0.2% |
| Free cash flow | $1.29B | $584.0M | +121% |

Page: https://aapwire.com/stocks/MDT/earnings

## Annual figures (fiscal years)

| Measure | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $29.71B | $29.95B | $30.56B | $28.91B | $30.12B | $31.69B | $31.23B | $32.36B | $33.54B | $36.36B |
| Revenue growth | +3.0% | +0.8% | +2.0% | −5.4% | +4.2% | +5.2% | −1.4% | +3.6% | +3.6% | +8.4% |
| Gross profit | $20.42B | $20.90B | $21.40B | $19.49B | $19.63B | $21.54B | $20.51B | $21.15B | $21.91B | $23.64B |
| Operating income | $5.38B | $6.64B | $6.27B | $4.79B | $4.48B | $5.75B | $5.49B | $5.14B | $5.96B | $6.47B |
| Net income | $4.03B | $3.10B | $4.63B | $4.79B | $3.61B | $5.04B | $3.76B | $3.68B | $4.66B | $4.80B |
| Diluted EPS | $2.89 | $2.27 | $3.41 | $3.54 | $2.66 | $3.73 | $2.82 | $2.76 | $3.61 | $3.73 |
| Operating cash flow | $6.88B | $4.68B | $7.01B | $7.23B | $6.24B | $7.35B | $6.04B | $6.79B | $7.04B | $7.33B |
| Capital expenditure | $1.25B | $1.07B | $1.13B | $1.21B | $1.35B | $1.37B | $1.46B | $1.59B | $1.86B | $1.90B |
| Free cash flow | $5.63B | $3.62B | $5.87B | $6.02B | $4.88B | $5.98B | $4.58B | $5.20B | $5.18B | $5.43B |
| Gross margin | 68.7% | 69.8% | 70.0% | 67.4% | 65.2% | 68.0% | 65.7% | 65.3% | 65.3% | 65.0% |
| Operating margin | 18.1% | 22.2% | 20.5% | 16.6% | 14.9% | 18.2% | 17.6% | 15.9% | 17.8% | 17.8% |
| Net margin | 13.6% | 10.4% | 15.2% | 16.6% | 12.0% | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% |
| Cash and equivalents | $4.97B | $3.67B | $4.39B | $4.14B | $3.59B | $3.71B | $1.54B | $1.28B | $2.22B | $1.95B |
| Total debt | $33.37B | $25.75B | $25.39B | $25.86B | $27.40B | $24.98B | $25.41B | $26.05B | $29.63B | $29.15B |
| Shareholders' equity | $50.21B | $50.72B | $50.09B | $50.74B | $51.43B | $52.55B | $51.48B | $50.21B | $48.02B | $49.46B |
| Diluted shares | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.3B | 1.3B | 1.3B | 1.3B |
| Dividends per share | $1.72 | $1.84 | $2.00 | $2.16 | $2.32 | $2.52 | $2.72 | $2.76 | $2.80 | $2.84 |

## Quarterly figures (last eight fiscal quarters)

| Measure | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $8.40B | $8.29B | $8.93B | $8.58B | $8.96B | $9.02B | $9.81B | $9.76B |
| Revenue, year on year | +5.2% | +2.5% | +3.9% | +8.4% | +6.6% | +8.7% | +9.9% | +13.7% |
| Gross margin | 64.9% | 66.5% | 64.7% | 65.0% | 65.8% | 63.8% | 65.4% | 65.0% |
| Operating income | $1.59B | $1.65B | $1.44B | $1.45B | $1.69B | $1.46B | $1.87B | $1.76B |
| Net income | $1.27B | $1.29B | $1.06B | $1.04B | $1.37B | $1.14B | $1.24B | $1.47B |
| Diluted EPS | $0.99 | $1.01 | $0.82 | $0.81 | $1.07 | $0.89 | $0.97 | $1.14 |
| Free cash flow | $554.0M | $2.10B | $2.07B | $584.0M | $457.0M | $2.30B | $2.08B | $1.29B |

## Operating KPIs

| KPI | Latest | Period | Change on a year |
| --- | ---: | --- | --- |
| [Electrophysiology Therapies revenue](https://aapwire.com/stocks/MDT/kpi/electrophysiology-therapies-revenue) | $2.2B | quarter to 31 Jul 2026 | up 29.6% |
| [Surgical & Endoscopy revenue](https://aapwire.com/stocks/MDT/kpi/surgical-and-endoscopy-revenue) | $1.7B | quarter to 31 Jul 2026 | up 8.7% |
| [Cranial & Spinal Technologies revenue](https://aapwire.com/stocks/MDT/kpi/cranial-and-spinal-technologies-revenue) | $1.4B | quarter to 31 Jul 2026 | up 12.7% |
| [Structural Heart & Aortic revenue](https://aapwire.com/stocks/MDT/kpi/structural-heart-and-aortic-revenue) | $1.0B | quarter to 24 Apr 2026 | up 6.3% |
| [Specialty Therapies revenue](https://aapwire.com/stocks/MDT/kpi/specialty-therapies-revenue) | $774.0M | quarter to 31 Jul 2026 | up 10.3% |
| [Coronary & Peripheral Vascular revenue](https://aapwire.com/stocks/MDT/kpi/coronary-and-peripheral-vascular-revenue) | $685.0M | quarter to 24 Apr 2026 | up 3.9% |
| [Acute Care & Monitoring revenue](https://aapwire.com/stocks/MDT/kpi/acute-care-and-monitoring-revenue) | $539.0M | quarter to 31 Jul 2026 | up 14.4% |
| [Neuromodulation revenue](https://aapwire.com/stocks/MDT/kpi/neuromodulation-revenue) | $539.0M | quarter to 31 Jul 2026 | up 4.9% |
| [Reportable segment net sales](https://aapwire.com/stocks/MDT/kpi/reportable-segment-net-sales) | $8.9B | quarter to 31 Jul 2026 | up 14.1% |
| [Cardiovascular revenue](https://aapwire.com/stocks/MDT/kpi/cardiovascular-revenue) | $3.9B | quarter to 31 Jul 2026 | up 19.5% |
| [Neuroscience revenue](https://aapwire.com/stocks/MDT/kpi/neuroscience-revenue) | $2.7B | quarter to 31 Jul 2026 | up 10.3% |
| [Medical Surgical revenue](https://aapwire.com/stocks/MDT/kpi/medical-surgical-revenue) | $2.3B | quarter to 31 Jul 2026 | up 9.9% |
| [Diabetes revenue](https://aapwire.com/stocks/MDT/kpi/diabetes-revenue) | $843.0M | quarter to 31 Jul 2026 | up 16.9% |
| [United States revenue](https://aapwire.com/stocks/MDT/kpi/united-states-revenue) | $4.9B | quarter to 31 Jul 2026 | up 16.1% |
| [International revenue](https://aapwire.com/stocks/MDT/kpi/international-revenue) | $4.9B | quarter to 31 Jul 2026 | up 11.4% |
| [Rest of world revenue](https://aapwire.com/stocks/MDT/kpi/rest-of-world-revenue) | $4.8B | quarter to 31 Jul 2026 | up 11.3% |
| [Ireland revenue](https://aapwire.com/stocks/MDT/kpi/ireland-revenue) | $40.0M | quarter to 31 Jul 2026 | up 21.2% |

## Method

Each period is read from the report the company filed and checked against accounting identities; a figure that does not pass is left blank (—), never estimated. Free cash flow is operating cash flow less capital expenditure. Diluted EPS is as the company reported it, adjusted for later stock splits. Research information only, not investment advice.
